Table 3:
iMCD patients considered to have HV histopathology treated with anti-IL-6 therapy in the real world
| Published literature* | Clinical subtype | Responses | Total cases | Responders that relapsed on therapy prior to publication |
|---|---|---|---|---|
| Anti-IL-6 ± CS | iMCD-TAFRO | 9 | 13 | 3 |
| Anti-IL-6 + rituximab or cyclosporine ± CS | iMCD-TAFRO | 5 | 5 | 3 |
| UAMS experience | ||||
| Anti-IL-6 ± CS | iMCD-TAFRO | 4 | 4 | 0 |
| Anti-IL-6 ± CS | iMCD-NOS | 7 | 7 | 0 |
CS, corticosteroids; anti-IL-6, anti-interleukin-6 therapy including siltuximab or tocilizumab
*
Citations: Sakai et al, 2018; Fujiwara et al, 2016; Fajgenbaum et al, 2019; Pai et al, 2020; Smith et al, 2014; Mizuno et al, 2018; Sakashita et al, 2016; Angenendt et al, 2015; Iwaki et al, 2013; José et al, 2017; Behnia et al, 2017; Takayama et al, 2018; Miatech et al, 2019.